New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 27, 2014
08:01 EDTRNAProsensa awarded $200K research grant
Prosensa announced that Judith van Deutekom, Prosensa's vice president of drug discovery, has been awarded a $200K research grant from Parent Project Muscular Dystrophy to fund the development of a multi exon-skipping strategy for exons 10-30 of the dystrophin gene. The project titled "Single AON-induced multiple exon skipping in the mdx mouse model" will focus on obtaining proof-of-concept in the mdx mouse model. The studies are expected to be completed in 2H15.
News For RNA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 20, 2014
06:50 EDTRNAProsensa upgraded to Overweight from Underweight at JPMorgan
JPMorgan upgraded Prosensa two notches to Overweight citing a favorable risk/reward around the potential approval of Drisapersen for Duchenne muscular dystrophy. The firm believes regulatory risk for the drug has been significantly reduced in both the U.S. and Europe. JPMorgan raised its price target for shares to $18 from $4.40.
October 10, 2014
10:12 EDTRNAProsensa begins NDA submission to FDA for drisapersen
Subscribe for More Information
October 7, 2014
10:05 EDTRNAProsensa has a conference call hosted by JPMorgan
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use